Multiple Ascending Dose (MAD) Combination in Subjects With Multiple Myeloma
NCT00884546
Completed
To evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of BMS-833923 administered alone, in combination with lenalidomide plus dexamethasone, or in combination with bortezomib in subjects with relapsed or refractory multiple myeloma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/28/2016
Locations: City Of Hope National Medical Center, Duarte, California +7 locations
Conditions: Advanced Cancer, Various, NOS
Register for Updates
Disrupting the Bone Marrow Microenvironment With G-CSF in Acute Lymphoblastic Leukemia
NCT01331590
Completed
The purpose of this study is to determine the ability of G-CSF to disrupt the bone marrow microenvironment as a means to increase the efficacy of chemotherapy in patients with relapsed or refractory acute lymphoblastic leukemia (ALL).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/19/2016
Locations: University of Chicago Medical Center, Chicago, Illinois +1 locations
Conditions: Precursor Cell Lymphoblastic Leukemia-Lymphoma
Register for Updates
Carfilzomib in Treating Patients With Multiple Myeloma in First Relapse or Refractory to First-Line Therapy
NCT02020941
Terminated
This phase II trial studies how well carfilzomib works in treating patients with multiple myeloma in first relapse or refractory to first-line therapy. Carfilzomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/14/2016
Locations: Indiana University Cancer Center, Indianapolis, Indiana
Conditions: Refractory Multiple Myeloma
Register for Updates
Revlimid / All-Trans Retinoic Acid (ATRA) / Dexamethasone in Relapsed/Refractory Multiple Myeloma
NCT01985477
Terminated
The goal of the Phase I portion of this clinical research study is to find the highest tolerated dose of the combination of lenalidomide, all-trans retinoic acid (ATRA), and dexamethasone that can be given to patients with relapsed or refractory multiple myeloma (MM). The goal of the Phase II portion of this study is to learn if ATRA when given in combination with lenalidomide alone or with lenalidomide and dexamethasone can help to control multiple myeloma. In September 2015, the study was te... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/12/2016
Locations: University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Myeloma
Register for Updates
Lenalidomide, Rituximab, Cyclophosphamide, and Dexamethasone in Treating Patients With Previously Untreated Low-Grade Non-Hodgkin Lymphoma
NCT00784927
Completed
RATIONALE: Lenalidomide may stop the growth of cancer cells by blocking blood flow to the cancer. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Drugs used in chemotherapy, such as cyclophosphamide and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopp... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
08/25/2016
Locations: Mayo Clinic in Arizona, Scottsdale, Arizona +1 locations
Conditions: Lymphoma
Register for Updates
Diabetic Macular Edema Treated With Ozurdex (DMEO)
NCT01951066
Completed
To measure various pro-permeability factors in the aqueous humor of patients with persistent/recurrent diabetic macular edema
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
08/23/2016
Locations: Wilmer Eye Institute, Baltimore, Maryland
Conditions: Diabetic Macular Edema
Register for Updates
Decreasing Narcotics in Advanced Pelvic Surgery
NCT02110719
Completed
In recent years, there has been an emphasis on the creation of "enhanced-recovery", "fast-track" or "multi-modal" pathways to improve perioperative care (1-4). The goal of these programs is to reduce the length of hospital stay, decrease narcotic usage while improving pain control, accelerate post-operative recovery, and expedite return to baseline functional status. Pathways often are developed by a team of surgeons, nurses, pain specialists, anesthesiologists and other support staff. Postopera... Read More
Gender:
FEMALE
Ages:
Between 18 years and 100 years
Trial Updated:
08/15/2016
Locations: Hartford Hosptial, Hartford, Connecticut
Conditions: Narcotic Use, Pain, Constipation, Nausea
Register for Updates
Open-label, Multli-center, Phase 1b/2a Clinical Trial Designed to Evaluate the Safety and Efficacy of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution in Patients With Macular Edema
NCT02485249
Terminated
To evaluate the safety and efficacy of ocular iontophoresis with dexamethasone phosphate ophthalmic solution, EGP-437, using the EyeGate® II Drug Delivery System (EGDS) in patients with macular edema (ME)
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
08/01/2016
Locations: Ophthalmic Consultants of Boston, Boston, Massachusetts
Conditions: Macular Edema
Register for Updates
Dexamethasone Intravitreal Implant After Vitrectomy For Epiretinal Membrane
NCT01410201
Terminated
The purpose of this study is to evaluate the effect of dexamethasone intravitreal implant (Ozurdex) in combination with pars plana vitrectomy and membrane peeling for idiopathic epiretinal membrane (ERM).
Gender:
ALL
Ages:
All
Trial Updated:
07/26/2016
Locations: St. Lukes Hospital, Chesterfield, Missouri +2 locations
Conditions: Epiretinal Membrane, Macular Edema
Register for Updates
Chemotherapy and Whole-Brain Radiation Therapy in Treating Patients With Primary Central Nervous System Non- Hodgkin's Lymphoma
NCT00002676
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining radiation therapy with chemotherapy may kill more tumor cells and may be an effective treatment for non-Hodgkin's lymphoma. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy and whole-brain radiation therapy in patients with primary central nervous system non-Hodgkin's lymph... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
07/12/2016
Locations: CCOP - Scottsdale Oncology Program, Scottsdale, Arizona +20 locations
Conditions: Lymphoma
Register for Updates
Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer
NCT00002716
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. It is not yet known which chemotherapy regimen is more effective for metastatic colorectal cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of intrahepatic floxuridine, leucovorin, and dexamethasone with that of systemic fluorouracil and leucovorin in treating patients who have unresectable liver... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/12/2016
Locations: CCOP - Cedar Rapids Oncology Project, Cedar Rapids, Iowa +13 locations
Conditions: Colorectal Cancer, Metastatic Cancer
Register for Updates
Dasatinib in Combination With Revlimid (and Dexamethasone)
NCT00560391
Completed
The purpose of this study was to determine the safety and tolerability of dasatinib when given in combination with lenalidomide and a low dose dexamethasone for the treatment of relapsed or refractory multiple myeloma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/06/2016
Locations: Mayo Clinic Arizona, Scottsdale, Arizona +3 locations
Conditions: Multiple Myeloma
Register for Updates